L’evento è accreditato per:
MEDICO CHIRURGO specialista in:
neurologia; neuropsichiatria infantile; psichiatria
FARMACISTA: farmacia ospedaliera
N. PARTECIPANTI: 100
CREDITI FORMATIVI: 2
Schizophrenia is a severe mental disease that affects approximately 1% of the population with a relevant chronic impact on social and occupational functioning in daily activities.
People with schizophrenia are 2-2.5 times more likely to die earlier than general population. Non-adherence to antipsychotic medications, both in chronic and first episode, is one of the most important risk factors for relapse and hospitalization.
The symposium aims to illustrate the new treatments for schizophrenia disorder, in particular it focuses on atypical long-acting injectable antipsychotics and provides information for an effective and personalized treatment. Special attention will be devoted to early treatment and first episode, as well as the management of the maintenance phase.
Key points of discussion will be promotion of patient recovery strategies and improvement of quality of life.
Caricamento in corso…